BioGend Therapeutics Co., Ltd. (TPEX:6733)

BioGend Therapeutics Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	225.56	219.02	330.51	163.64	136.32	120.04
Short-Term Investments	350	400	393.76	329.76	552.96	392.99
Cash & Short-Term Investments	575.56	619.02	724.27	493.4	689.28	513.03
Cash Growth	-12.22%	-14.53%	46.79%	-28.42%	34.36%	38.74%
Accounts Receivable	50.03	47.36	26.69	11.27	5.05	0.28
Other Receivables	1.28	33.37	30.67	28.25	23.61	21.62
Receivables	51.31	80.72	57.36	39.52	28.66	21.89
Inventory	16.33	15.96	16.55	4.9	9.03	10.41
Prepaid Expenses	32.52	2	3	4.07	7.57	1.42
Total Current Assets	675.72	717.7	801.18	541.89	734.54	546.75
Property, Plant & Equipment	45.11	49.57	56.2	34.01	8.89	5.94
Long-Term Investments	7.65	8.33	20.34	10	-	69.43
Goodwill	-	17.09	17.09	17.09	17.09	-
Other Intangible Assets	110.44	114.07	151.04	210.95	261.92	102.29
Other Long-Term Assets	6.39	5.94	4.64	7.89	1.42	0.94
Total Assets	845.31	912.7	1,050	821.82	1,024	725.34
Accounts Payable	1.61	4.22	2.16	2.08	0.49	1.36
Accrued Expenses	-	20.61	16.57	17.22	14.39	14.19
Current Portion of Leases	3.39	3.59	3.65	3.49	3.94	-
Other Current Liabilities	26.38	4.81	23.87	9.07	6.3	2.72
Total Current Liabilities	31.38	33.23	46.25	31.86	25.13	18.27
Long-Term Leases	4.19	5.84	9.44	12.28	0.48	-
Long-Term Unearned Revenue	-	-	2.5	2.5	2.5	2.5
Long-Term Deferred Tax Liabilities	22.93	27.13	35.52	43.92	52.31	-
Total Liabilities	58.49	66.19	93.71	90.56	80.42	20.77
Common Stock	1,243	1,243	1,231	1,031	1,031	920
Additional Paid-In Capital	-	-	-	-	212.85	160.9
Retained Earnings	-454.8	-398.32	-281.85	-325.52	-353.91	-376.33
Comprehensive Income & Other	-23.88	-26.58	-7.96	-2.38	-2.16	-
Total Common Equity	763.89	817.67	940.96	702.86	887.54	704.57
Minority Interest	22.93	28.84	15.81	28.4	55.91	-
Shareholders' Equity	786.82	846.51	956.77	731.27	943.45	704.57
Total Liabilities & Equity	845.31	912.7	1,050	821.82	1,024	725.34
Total Debt	7.58	9.43	13.09	15.77	4.42	-
Net Cash (Debt)	567.98	609.59	711.18	477.64	684.86	513.03
Net Cash Growth	-11.87%	-14.28%	48.90%	-30.26%	33.49%	38.74%
Net Cash Per Share	4.64	4.95	5.91	4.63	6.76	5.87
Filing Date Shares Outstanding	122.06	124.26	123.08	103.08	103.08	92
Total Common Shares Outstanding	122.06	124.26	123.08	103.08	103.08	92
Working Capital	644.34	684.47	754.93	510.03	709.42	528.47
Book Value Per Share	6.26	6.58	7.65	6.82	8.61	7.66
Tangible Book Value	653.45	686.51	772.83	474.82	608.52	602.28
Tangible Book Value Per Share	5.35	5.52	6.28	4.61	5.90	6.55
Machinery	-	31.6	31.19	24.66	24.55	23.87
Construction In Progress	-	-	37.57	14.91	-	-
Leasehold Improvements	-	38.15	0.34	0.34	0.34	3.03

Source: S&P Global Market Intelligence. Standard template. Financial Sources.